nct_id: NCT06876662
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2025-03-14'
study_start_date: '2025-05-20'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Pirtobrutinib'
long_title: Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001
  With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  or Non-Hodgkin Lymphoma
last_updated: '2025-11-20'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE4
principal_investigator: NA
principal_investigator_institution: Eli Lilly and Company
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 279
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Are currently enrolled and active in the originator study, LOXO-BTK-18001. A
  participant is considered active in the study if they are:'
- '* receiving study intervention'
- '* in the short-term follow-up period, or'
- '* in the long-term follow-up period'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
short_title: A Study of (LY3527727) Pirtobrutinib in Participants With Previously
  Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Eli Lilly and Company
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master
  protocol J2N-MC-JZNY, and represents participants from the completed originator
  study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator
  study will have the opportunity to continue their assigned study intervention or
  continue their follow-up visits by transitioning to this study. This study will
  evaluate the long-term safety and efficacy of pirtobrutinib.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: JZ01 Pirtobrutinib
      arm_internal_id: 0
      arm_description: 'Participants receive pirtobrutinib as defined in the originator
        study (LOXO-BTK-18001/J2N-OX-JZNA).


        Pirtobrutinib administered orally.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pirtobrutinib'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        oncotree_primary_diagnosis: Lymphoid Neoplasm
